Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — AusBiotech Broker Meets Biotech, Perth 2015
17 slides from Proteomics International Laboratories's conference presentation, Sep 2, 2015
Slide 1: Investor Presentation | AusBiotech Broker Meets Biotech, Perth
Proteomics International Laboratories Ltd For personal use only Investor Presentation | AusBiotech Broker Meets Biotech, Perth | 2nd September 2015 Global leader & innovator in the field of proteomics ASX: PIQ 1 Proteomics International Laboratories Ltd
Slide 2: Disclaimer & forward-looking statements
Disclaimer & forward-looking statements For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 3: Corporate overview
Corporate overview For personal use only Capital Structure Shareholders ASX code PIQ Top 20 Shareholders 69.3% Shares on issue 50.6m Major Shareholders Listed (@ 20c) 16th April 2015 Richard Lipscombe 31.9% XYLO Pty Ltd 12.4% Market capitalisation (@ 36c) $18.2m John Dunlop 7.5% 4 month price range
Slide 4: Introducing PIQ
Introducing PIQ For personal use only Revenue generating Company – Established 2001 Global leader & innovator in field of proteomics World’s first company to receive ISO 17025 laboratory accreditation for proteomics services Proven technology with established IP Operates from purpose built, state-of
Slide 5: Engaged in high growth markets
Engaged in high growth markets For personal use only Diagnostics (biomarkers) market is $24.1bn 1 Predicted to reach $45.6bn by 2020 1. ‘Omics’ technology holds ~75% share. Proteomics market to be $20.8bn by 2018 2 Bio-engineered protein drugs was $152bn (2013) CAGR 7.2%. 7 of world's top 10 selling
Slide 6: Business model
Business model For personal use only Three synergistic business units Unifying platform technology - leverage & efficiency Existing revenue generation & deal flow - multiple major upside opportunities 6 Proteomics International Laboratories Ltd
Slide 7: Diagnostics – personalised testing
For personal use only Diagnostics – personalised testing Unlike our genes, the protein make-up in our bodies changes considerably over time – e.g. a cancerous cell will have significantly different proteins to a healthy cell. PIQ's proteomics-based technology platform is developing next generation d
Slide 8: Predictive test for diagnosis of diabetic kidney disease
Predictive test for diagnosis of diabetic kidney disease For personal use only International Diabetes Foundation estimates 387 million people globally have diabetes; in Australia alone, total cost to the health system and productivity loss is ~$10bn annually According to US Centre for Disease Contro
Slide 9: Why PIQ?
Why PIQ? For personal use only Leveraged business model Established income ~$1m per annum reduces burn Analytics division underpins cash flow (revenue grew 27% in 2015) Strong IP position Patents pending in major jurisdictions for ground-breaking PromarkerD diagnostic Proven technology platform Proo
Slide 10: For personal use only
For personal use only 10 Proteomics International Laboratories Ltd
Slide 11: Supplemental: Changing lives
Supplemental: Changing lives...... For personal use only DNA shapes our lives. The Human Genome Project, to map human DNA, was the single largest undertaking in the history of biological science. Completed in 2003 it was a US$4 billion international collaboration. Today, cumulative benefits are esti
Slide 12: Supplemental: Board & management
Supplemental: Board & management For personal use only Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology L
Slide 13: Supplemental: Proprietary platform technology
Supplemental: Proprietary platform technology For personal use only One proven and proprietary platform, multiple uses: • Diagnostics - biomarker discovery • Analytics - biosimilars testing • Therapeutics - drug discovery The methodology was developed as part of a $7m self-funded R&D program 13 Prot
Slide 14: Supplemental: Transactions in our sector
Supplemental: Transactions in our sector For personal use only Proteome Sciences (AIM: PRM) Biomarker discovery, validation and assay development in Alzheimer's, breast cancer & cosmetics. Revenue GBP1.56m in 2014; raised A$5m June 2015; market cap A$80m (14th Aug 15). Applied Proteomics Inc, privat
Slide 15: Supplemental: Analytical services
For personal use only Supplemental: Analytical services PIQ offers one of the world’s only internationally accredited laboratories for proteomics analysis. This analytical services business leverages its proteomics technology platform’s ability to test & validate the protein composition of a wide ra
Slide 16: Supplemental: Analytical services
Supplemental: Analytical services For personal use only Proven track record in analysing protein drugs Blue chip, global client base with 50% export income (priced in USD) Analytical & consulting services income in 2015 grew 27% year on year Major contracts post listing: a2 Milk Company (quality con
Slide 17: Please contact
Please contact For personal use only Richard Lipscombe Managing Director, Proteomics International E: enquiries@proteomicsinternational.com T: +61 8 9389 1992 www.proteomicsinternational.com Chuck Morrison Head of Business Development E: c.morrison@proteomicsinternational.com James Moses Greg Wood I
Proteomics International Laboratories — AusBiotech Broker Meets Biotech, Perth 2015 on 6ix